EXHIBIT
31.1








CERTIFICATION
PURSUANT TO RULE 13a-14(a)/15d-14(a)


OF
THE SECURITIES EXCHANGE ACT OF 1934





In
connection with the Quarterly Report of DOR BioPharma, Inc. (the “Company”) on
Form 10-Q for the fiscal quarter ended March 31, 2008, as filed with the
Securities and Exchange Commission on the date hereof, I, Christopher J.
Schaber, Ph.D., President and Chief Executive Officer of the Company, certify,
pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934,
that:





1. I have
reviewed the Quarterly Report on Form 10-Q of the Company for the fiscal quarter
ended March 31, 2008;





2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;





3. Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;





4. The
registrant’s other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:





(a)           Designed
such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this report is being prepared;





(b)           Designed
such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;





(c)           Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and





(d)           Disclosed
in this report any change in the registrant’s internal control over financial
reporting that occurred during the registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and





5. The
registrant’s other certifying officer and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):





(a)           All
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to
adversely affect the r registrant’s ability to record, process, summarize
and report financial information; and





(b)           Any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant’s internal control over financial
reporting.








DOR
BIOPHARMA, INC.





May
      15, 2008
            by:
            /s/ Christopher J.
  SchaberChristopher
      J. Schaber, Ph.D.President
      and Chief Executive Officer(Principal
      Executive Officer)